Get our introductory offer at only
$0
.99*/month
Cancel anytime
*$0.99/month for first 3 months
$29.90/month for the next 9 months
You are here
Roche drug cocktail doubles chance of holding lung cancer at bay
Zurich
ADDING Roche's immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease advancing, an outcome that some experts labelled as unprecedented.
Thirty-seven per cent of patients in a closely watched clinical...
Please log in to continue reading.
